Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of XNW14010 in advanced solid tumors with KRAS G12C mutation
CTR20221024Phase 2Terminated
- Sponsor
- Sinovent
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of XNW14010 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), colorectal cancer (CRC), sponsored by Sinovent. Started Dec 2022; status: terminated.
02
Drugs
XNW14010
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20221024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221024.